This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00
BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2
We asked them to explain how the company has integrated its isotopic labeling and human ADME testing services to help streamline the drug development process and accelerate the time it takes to get drugs to market. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.
In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Oral Bioavailability: Developing small molecules that are effectively absorbed when administered orally, while also being stable in the digestive system, can be complex.
Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it to the top of the world’s biggest-selling medicines. . However, Pfizer has a plan to get the franchise back on track, as it also faces the risk of a competitor reaching the market from Merck & Co.
Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market. Today, they are still thought to represent approximately two-thirds of all medicines administered through prescription and over-the-counter. The Frewitt Technology Centre is your address for process development.
Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Takeda wins big in cytomegalovirus infection market.
The risk factors for SLE include the medicines that induce lupus, age, race/ethnicity, and family history. It is also available as a generic medicine. As per DelveInsight’s report on Benlysta (Belimumab) market forecast , the sale of Belimumab has kept on increasing year after year. Anifrolumab (MEDI-546).
Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.
Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics and a wholly owned subsidiary of the Menarini Group, will market Orserdu in the US. ER+, HER2- Breast Cancer ER+, HER2- cancers account for about 75 percent of breast cancers.
Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch.
Understanding the polymorphism of a drug compound plays a key role in both drug substance and drug product development, because it can negatively impact the downstream stability, solubility, and bioavailability of a drug. Streamlined processes to reduce time to market for drugs. Integrated drug substance and drug product services.
Innovations in Skin Cancer Treatment: Precision Medicine and Immunotherapy Treatment options for skin cancer have considerably evolved with a growing emphasis on precision medicine and immunotherapy. Precision medicine allows more effective and personalized treatment plans, which minimizes side effects and improves patient outcomes.
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir. About Ridgeback Biotherapeutics.
By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.
This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Nanoform is an innovative nanoparticle medicine enabling company. HELSINKI , Nov. Finnish time.
The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.
Additionally, it increases the bioavailability and solubility of the attached molecule. In fact, in the last twenty years, the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA) have authorized the market approval of around 80 nanomedicines.
4, 2021 /PRNewswire/ — Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. HELSINKI , Jan.
Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine. About XPhyto Therapeutics Corp.
Notably, these presentations include new data from dose proportionality and bioequivalence studies, which supported the FDA approval of once-daily AUSTEDO XR extended-release tablets – demonstrating AUSTEDO XR is therapeutically equivalent to the currently marketed twice-daily AUSTEDO. Source link: [link]
Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 SAN DIEGO, Dec. About Kura Oncology.
And the unique Japanese mushroom trio – Maitake, Reishi and Shiitake- which were proven to have incredible health properties by one study in the Journal of Oxidative Medicine and Cellular Longevity! Frank Neal is a pen name used for marketing purposes and to protect the author’s identity.
Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. About Maribavir.
These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies. Several compounds are being further optimized for preclinical studies. Details can be found at this link.
LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Photo: Business Wire). PureTech is also advancing LYT-100 for the treatment of IPF and is actively planning additional PK and dosing studies. About PureTech Health.
Last May, Lilly’s first-in-class oral precision medicine, Retevmo received Accelerated Approval from the U.S. Presentation Title: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD). Portfolio Highlights. Abstract Number: 1236. Retevmo is an U.S.
CNS drugs take more than a year longer to develop and are less than half as likely to receive marketing approval compared to other drugs, according to a 2014 study by the Tufts Center for the Study of Drug Development. Targeting the CNS directly has been successful in modern medicine. Why is it Difficult to Develop CNS Therapeutics?
The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is covered by more than 93 issued U.S. and international patents which provide protection out to 2040. Axsome Therapeutics, Inc.
and could change how “bioavailable” the all-important EBM triggering nutrients are. Bioavailable is a word that scientists use to describe how easy it is for your body to use a nutrient…. Had many different fermentation methods that people used to preserve foods.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content